{"id":1152,"date":"2025-05-12T12:15:49","date_gmt":"2025-05-12T12:15:49","guid":{"rendered":"https:\/\/lifescience.nanografi.com\/uncategorized-tr\/hpv-types-warts-and-cancer-risk\/"},"modified":"2026-07-30T11:57:29","modified_gmt":"2026-07-30T11:57:29","slug":"hpv-types-warts-and-cancer-risk","status":"publish","type":"post","link":"https:\/\/lifescience.nanografi.com\/tr\/uncategorized-tr\/hpv-types-warts-and-cancer-risk\/","title":{"rendered":"HPV: Types, Warts, and Cancer Risk"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Human papillomavirus (HPV) is a non-enveloped, double-stranded DNA virus of the Papillomaviridae family. <\/strong><\/p>\n\n<p class=\"wp-block-paragraph\">To date, over 200 genotypes have been identified, classified by DNA sequence homology in the viral L1 gene. These genotypes exhibit distinct tissue tropisms\u2014cutaneous or mucosal\u2014and variable oncogenic potential. <a href=\"https:\/\/lifescience.nanografi.com\/blog\/what-is-hpv-a-comprehensive-overview\/\" data-type=\"link\" data-id=\"https:\/\/lifescience.nanografi.com\/blog\/what-is-hpv-a-comprehensive-overview\/\">Understanding HPV<\/a> classification guides clinical management, screening strategies, and preventive measures (World Health Organization, 2023). <\/p>\n\n<h2 class=\"wp-block-heading has-medium-font-size\">1. Cutaneous versus Mucosal HPV<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><strong>Cutaneous HPVs<\/strong> infect keratinized epidermis, producing common (verruca vulgaris), plantar, and flat warts. Predominant cutaneous types include HPV-1, -2, -3, -4, and -10. <\/li>\n\n\n\n<li><strong>Mucosal HPVs<\/strong> target non-keratinized squamous epithelium of the anogenital tract and oropharynx. Approximately 40 mucosal genotypes exist, subdivided by their clinical outcomes into low-risk (LR) and high-risk (HR) categories (World Health Organization, 2023). <\/li>\n<\/ul>\n\n<h2 class=\"wp-block-heading has-medium-font-size\">2. Low-Risk HPV Genotypes<\/h2>\n\n<p class=\"wp-block-paragraph\">Low-risk HPVs rarely lead to malignancy; they induce benign proliferations:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>HPV-6 and HPV-11<\/strong>\n<ul class=\"wp-block-list\">\n<li>Responsible for over 90 % of anogenital warts (condylomata acuminata).<\/li>\n\n\n\n<li>Also cause recurrent respiratory papillomatosis, characterized by airway-obstructing papillomas (National Cancer Institute, 2022).<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Other LR types<\/strong> (e.g., HPV-40, -42, -43, -44, -54) can produce genital warts less frequently.<\/li>\n<\/ul>\n\n<p class=\"wp-block-paragraph\">Although non-oncogenic, LR infections may recur and require repeated treatment.<\/p>\n\n<h2 class=\"wp-block-heading has-medium-font-size\">3. High-Risk HPV Genotypes<\/h2>\n\n<p class=\"wp-block-paragraph\">High-risk HPVs encode E6 and E7 oncoproteins that inactivate p53 and retinoblastoma (pRb) tumor suppressors, promoting cellular immortalization and carcinogenesis if infection persists (Centers for Disease Control and Prevention, 2024).<\/p>\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Genotype<\/strong><\/td><td><strong>Approximate Contribution to Cervical Cancer<\/strong><\/td><\/tr><tr><td><strong>HPV-16<\/strong><\/td><td>\u2248 60 % of cervical cancers; also prominent in oropharyngeal carcinomas<\/td><\/tr><tr><td><strong>HPV-18<\/strong><\/td><td>\u2248 10\u201315 % of cervical cancers; overrepresented in adenocarcinomas<\/td><\/tr><tr><td><strong>HPV-31, -33, -45<\/strong><\/td><td>Together account for \u2248 10 % of cases<\/td><\/tr><tr><td><strong>HPV-52, -58<\/strong><\/td><td>Regionally significant; included in nonavalent vaccines<\/td><\/tr><tr><td><strong>Others (e.g., 35, 39, 51, 56, 59, 68)<\/strong><\/td><td>Less frequent but classified as oncogenic<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<p class=\"wp-block-paragraph\">Persistent HR infection increases risk of high-grade cervical intraepithelial neoplasia (CIN 2\/3) and invasive carcinoma over 10\u201320 years (National Cancer Institute, 2022).<\/p>\n\n<h2 class=\"wp-block-heading has-medium-font-size\">4. Implications for Screening and Prevention<\/h2>\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li><strong>Genotype-Specific Testing<\/strong>\n<ul class=\"wp-block-list\">\n<li>HPV DNA tests detect pooled HR types and can specifically identify HPV-16\/18, enabling risk stratification and timely referral to colposcopy (World Health Organization, 2023).<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Prophylactic Vaccination<\/strong>\n<ul class=\"wp-block-list\">\n<li><strong>Bivalent<\/strong> (HPV-16\/18), <strong>quadrivalent<\/strong> (adds HPV-6\/11), and <strong>nonavalent<\/strong> (adds HPV-31\/33\/45\/52\/58) vaccines can prevent up to 90 % of cervical cancers and most anogenital warts when administered before HPV exposure (Centers for Disease Control and Prevention, 2024).<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Surveillance and Epidemiology<\/strong>\n<ul class=\"wp-block-list\">\n<li>Ongoing monitoring of genotype prevalence post-vaccination informs on herd immunity effects and potential genotype replacement, guiding updates to vaccine composition (World Health Organization, 2023).<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Management of Lesions<\/strong>\n<ul class=\"wp-block-list\">\n<li><strong>Benign lesions<\/strong> (LR types): treated with cryotherapy, surgical excision, or topical agents (e.g., imiquimod).<\/li>\n\n\n\n<li><strong>Precancerous lesions<\/strong> (HR types, CIN 2\/3): managed via excisional procedures such as loop electrosurgical excision procedure (LEEP) or cold-knife conization to prevent progression (National Cancer Institute, 2022).<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n\n<p class=\"wp-block-paragraph\">HPV genotype classification by tropism and oncogenic risk is foundational to effective public health strategies. Cutaneous types cause benign warts; LR mucosal types induce condylomas and respiratory papillomas; HR types drive cervical and other anogenital\/oropharyngeal cancers. Genotype-specific diagnostics and widespread vaccination targeting the most oncogenic types are essential tools to reduce HPV-associated disease burden globally.<\/p>\n\n<p class=\"wp-block-paragraph\"><strong>References<\/strong><\/p>\n\n<p class=\"wp-block-paragraph\">Centers for Disease Control and Prevention. (2024). <em>HPV and cancer<\/em>. <a href=\"https:\/\/www.cdc.gov\/hpv\/about\/cancers-caused-byhpv.html?CDC_AAref_Val=https:\/\/www.cdc.gov\/hpv\/parents\/cancer.html\">https:\/\/www.cdc.gov\/hpv\/about\/cancers-caused-byhpv.html?CDC_AAref_Val=https:\/\/www.cdc.gov\/hpv\/parents\/cancer.html<\/a><\/p>\n\n<p class=\"wp-block-paragraph\">National Cancer Institute. (2022). <em>HPV and cancer: HPV infection and cervical cancer<\/em>. <a href=\"https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/risk\/infectious-agents\/hpv-fact-sheet\">https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/risk\/infectious-agents\/hpv-fact-sheet<\/a><\/p>\n\n<p class=\"wp-block-paragraph\">World Health Organization. (2023). <em>Human papillomavirus (HPV) and cervical cancer<\/em>. <a href=\"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/human-papillomavirus-(hpv)-and-cervical-cancer\">https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/human-papillomavirus-(hpv)-and-cervical-cancer<\/a><\/p>\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>To date, over 200 genotypes have been identified, classified by DNA sequence homology in the viral L1 gene. These genotypes exhibit distinct tissue tropisms, cutaneous or mucosal, and variable oncogenic potential. <\/p>\n","protected":false},"author":4,"featured_media":1005,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[50,51,52],"class_list":["post-1152","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized-tr","tag-hpv","tag-hpv-types","tag-hpv-wart-types"],"_links":{"self":[{"href":"https:\/\/lifescience.nanografi.com\/tr\/wp-json\/wp\/v2\/posts\/1152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifescience.nanografi.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifescience.nanografi.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifescience.nanografi.com\/tr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/lifescience.nanografi.com\/tr\/wp-json\/wp\/v2\/comments?post=1152"}],"version-history":[{"count":1,"href":"https:\/\/lifescience.nanografi.com\/tr\/wp-json\/wp\/v2\/posts\/1152\/revisions"}],"predecessor-version":[{"id":1153,"href":"https:\/\/lifescience.nanografi.com\/tr\/wp-json\/wp\/v2\/posts\/1152\/revisions\/1153"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lifescience.nanografi.com\/tr\/wp-json\/wp\/v2\/media\/1005"}],"wp:attachment":[{"href":"https:\/\/lifescience.nanografi.com\/tr\/wp-json\/wp\/v2\/media?parent=1152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifescience.nanografi.com\/tr\/wp-json\/wp\/v2\/categories?post=1152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifescience.nanografi.com\/tr\/wp-json\/wp\/v2\/tags?post=1152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}